Breaking News: P3 Health Partners Receives Nasdaq Notice for Late Filing of Periodic Report

P3 Health Partners Announces Receipt of Nasdaq Notice Regarding Late Filing of Periodic Report Introduction HENDERSON, Nev., Aug. 19, 2022 (GLOBE NEWSWIRE) — P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that on August 17, 2022 it received a notice (the “Notice”) from…

Read More

Emerald Health Therapeutics Shareholders Approve Plan of Arrangement with Skye Bioscience: A Promising Partnership in the World of Biotechnology

Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement San Diego, California, Aug. 19, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeutics, Inc. (“Emerald”…

Read More

Calling All Ampio Pharmaceuticals Inc. Investors: Don’t Miss Out on Legal Protection! Rosen Law Firm Urges You to Act Before the Securities Class Action Deadline

What You Need to Know About the Ampio Pharmaceuticals Class Action Lawsuit A Brief Overview In a recent announcement, the Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of purchasers of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) securities. The lawsuit covers a period between December 29,…

Read More

Breaking News: Vyant Bio Reschedules Investor Conference Call and Webcast for Q2 and First Half of 2022!

Vyant Bio Announces Rescheduled Investor Conference Call and Web… CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models…

Read More

Unlocking the Future of AI: Omniq CEO to Speak at Rosenblatt Securities’ 2nd Annual Technology Summit

OMNIQ Corp CEO to present at Rosenblatt Securities 2nd Annual Technology Summit What to expect from the presentation? OMNIQ Corp, a leader in Supply Chain and Artificial Intelligence solutions, will have key members of its management team participate in the Rosenblatt Securities 2nd Annual Technology Summit: The Age of AI Scaling. During the summit, the…

Read More